vimarsana.com
Home
Live Updates
Theseus Pharmaceuticals Reports Initial Dose Escalation Data
Theseus Pharmaceuticals Reports Initial Dose Escalation Data
Theseus Pharmaceuticals Reports Initial Dose Escalation Data from Ongoing Phase 1/2 Trial of THE-630 in Patients with Advanced GIST
-- THE-630 demonstrates encouraging safety profile through Cohort 6 (18 mg), supportive of continued dose escalation -- -- Dose-dependent reductions observed...
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
United States ,
Philadelphia ,
Pennsylvania ,
Christen Baglaneas ,
Tim Clackson ,
Suzanne George ,
David Kerstein ,
Josh Rappaport ,
Nasdaq ,
Theseus Pharmaceuticals Inc ,
Sarcoma Center ,
Exchange Commission ,
Dana Farber Cancer Institute ,
Theseus Pharmaceuticals ,
Clinical Development Plan ,
Corporate Communications Investor Relations ,
Predictive Resistance Assay ,
Chief Executive Officer ,
Associate Division Chief ,
Chief Medical Officer ,
Trial Background ,
Clinical Development ,
Theseu Form ,
Quarterly Reports ,
Corporate Communications ,